Just weeks after Novartis and Atlas Venture announced the launch of an upstart player in the fast-emerging field of CRISPR-Cas9 gene editing, the pharma giant has stepped back up to formally hammer out a partnership development deal and throw its enormous resources behind the biotech.
Qualcomm announced medical device-related partnerships with Walgreens and Novartis at the Consumer Electronics Show in Las Vegas. Qualcomm's contribution to the partnerships will be the cloud-based data-sharing Life2Net platform, described as a nonexclusive, interoperable system for delivering healthcare.
Bristol-Myers Squibb is turning to the California Institute for Biomedical Research (Calibr) in San Diego for new fibrosis drug candidates.
German contract researcher Evotec has paired off with Ohio State to help the school develop an in-house cancer prospect, lending its technology and expertise.
Amgen has found a CAR-T development partner. The Big Biotech is partnering up with Kite Pharma on new drugs that use Kite's chimeric antigen receptor tech, which turns T cells in the immune system into cancer-cell attack weapons. And they're both putting up some major milestone cash to fuel the work.
You can now count Johnson & Johnson among the roster of big companies to ally itself with Isis Pharmaceuticals' R&D group. J&J has stepped up with an $835 million pact to develop new drugs for autoimmune diseases of the gastrointestinal tract with the RNA specialists at Isis.
PPD has signed a deal with service provider Shin Nippon Biomedical Laboratories to collaborate in Japan, pooling resources in a joint venture designed to tap the growing market for clinical research there.
Eight months after OncoGenex Pharmaceuticals and Teva acknowledged that their experimental cancer drug custirsen had flopped in a Phase III prostate cancer study, the big Israeli pharma company has executed a strategic retreat from their partnership. Teva is handing over $27 million to OncoGenex to complete the divorce and is walking away from a deal that included $60 million in upfront costs back in 2009.
Two recent surveys covered by FierceDrugDelivery have shown that the vast majority of patients don't use their drug delivery devices properly. Device training specialist Noble says improved patient education is the key.
The prostate cancer experts at Medivation are getting into the hot field of checkpoint inhibitors for cancer, agreeing to pay Israel's CureTech as much as $335 million for the full rights to a promising Phase II asset.